Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13 - Université de Lorraine Accéder directement au contenu
Article Dans Une Revue Expert Opinion on Biological Therapy Année : 2021

Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13

Résumé

Biologic drugs have significantly improved the treatment of ulcerative colitis (UC) and Crohn's disease (CD). However, the availability of these drugs is limited by their high cost. Infliximab was the first biologic to be approved for inflammatory bowel diseases (IBD). After its patent expired other manufactures developed biosimilar versions, among which CT-P13, and licensed them thorough an expedite process.
Fichier non déposé

Dates et versions

hal-04214645 , version 1 (22-09-2023)

Identifiants

Citer

Tommaso Lorenzo Parigi, Ferdinando d'Amico, Laurent Peyrin-Biroulet, Silvio Danese. Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13. Expert Opinion on Biological Therapy, 2021, 21 (1), pp.37-46. ⟨10.1080/14712598.2020.1811849⟩. ⟨hal-04214645⟩
11 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More